Biodexa Pharmaceuticals has entered into agreements with institutional investors for a $5M financing through a registered direct offering and concurrent private placement. The offering includes 5,050,808 ADSs at $0.94 per share and 278,975 pre-funded warrants at $0.9399, with expected gross proceeds of approximately $5M before expenses.The concurrent private placement includes Series J warrants for 5,329,783 ADSs with a 5-year term and Series K warrants for 5,329,783 ADSs with a 1-year term, both at an exercise price of $1.00 per ADS. The company will also amend the exercise price of existing Series E, G, and H warrants to $1.00 per share for participating investors.Proceeds will primarily fund development programs, including the final match payment for a $17M CPRIT grant and initiation of Phase 3 clinical trial for eRapa in Familial Adenomatous Polyposis. Ladenburg Thalmann & Co. acts as sole placement agent, with the offering expected to close around July 22, 2024, subject to customary conditions.

Biodexa Pharmaceuticals has entered into agreements with institutional investors for a $5M financing through a registered direct offering and concurrent private placement. The offering includes 5,050,808 ADSs at $0.94 per share and 278,975 pre-funded warrants at $0.9399, with expected gross proceeds of approximately $5M before expenses.The concurrent private placement includes Series J warrants for 5,329,783 ADSs with a 5-year term and Series K warrants for 5,329,783 ADSs with a 1-year term, both at an exercise price of $1.00 per ADS. The company will also amend the exercise price of existing Series E, G, and H warrants to $1.00 per share for participating investors.Proceeds will primarily fund development programs, including the final match payment for a $17M CPRIT grant and initiation of Phase 3 clinical trial for eRapa in Familial Adenomatous Polyposis. Ladenburg Thalmann & Co. acts as sole placement agent, with the offering expected to close around July 22, 2024, subject to customary conditions.